Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human, Pilot PET Imaging Study of 89Zr-DFO-YS5, an immunoPET Agent for Detecting CD46 Positive Malignancy in Men With Prostate Cancer

NCT05245006 is registered in ClinicalTrials.gov with Robert Flavell, MD, PhD as lead sponsor.

NCT NCT05245006
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05245006 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human, Pilot PET Imaging Study of 89Zr-DFO-YS5, an immunoPET Agent for Detecting CD46 Positive Malignancy in Men With Prostate Cancer
Lead sponsor
Robert Flavell, MD, PhD
Phase
Phase 1
Overall status
Active, not recruiting
Start date
March 18, 2022
Completion date
July 31, 2027
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer, prostate cancer